Bayer Technology Services appoints head of Operation Support and Safety

Thomas Steckenreiter takes role as Norbert Kuschnerus retires

Thomas Steckenreiter is to become the divisional head of Operation Support & Safety at Bayer Technology Services (BTS).

Steckenreiter, currently director of marketing at Endress+Hauser Conducta in Gerlingen, Germany, will transfer to BTS on 1 July. He succeeds Norbert Kuschnerus, who retires on 30 June 30, after almost 30 years at Bayer.

Steckenreiter started his career as product manager at Mettler Toledo, before joining Endress+Hauser in 2001, holding various positions with global responsibility.

‘Dr Steckenreiter has solid experience in the fields of process safety and process analysis technology. He possesses special qualities that are key to the focused expansion of our portfolio and thus of our future business,’ said BTS’ managing director Dirk Van Meirvenne.

You may also like

Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Ingredients

Therapeutics: anticancer agent: larotrectinib

TRK (tropomyosin receptor kinase) fusion cancers occur when an NTRK gene fuses with another, unrelated gene, leading to the formation of an altered TRK protein
Ingredients

Therapeutics: darolutamide for prostate cancer

Prostate cancer is the second most commonly diagnosed cancer in men and leads to the fifth highest number of male cancer deaths
Media

Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead

Germany-based pharma major Bayer has recently received the European Commission approval for its haemophilia A long-acting injectable medicine Jivi
Regulatory

Australian beef and dairy industry welcomes registrations for tri-solfen

Patented pain relief product for animal husbandry procedures is marketed by Bayer in Australia
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

US-India relations stall over pharma IP squabble

IP protection for international pharmaceutical companies in India remains an unresolved issue, as India battles for affordable medicines and the US argues that better patent protection must be forthcoming. The potential of this huge market hangs in the balance as discussions continue
Subscribe now